DK2217704T3 - Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis - Google Patents

Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis Download PDF

Info

Publication number
DK2217704T3
DK2217704T3 DK08844273.6T DK08844273T DK2217704T3 DK 2217704 T3 DK2217704 T3 DK 2217704T3 DK 08844273 T DK08844273 T DK 08844273T DK 2217704 T3 DK2217704 T3 DK 2217704T3
Authority
DK
Denmark
Prior art keywords
mir
cell
molecule
antisense molecule
sequence
Prior art date
Application number
DK08844273.6T
Other languages
Danish (da)
English (en)
Inventor
Stefanie Dimmeler
Andreas M Zeiher
Angelika Bonauer
Carmen Urbich
Original Assignee
T2Cure Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T2Cure Gmbh filed Critical T2Cure Gmbh
Application granted granted Critical
Publication of DK2217704T3 publication Critical patent/DK2217704T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08844273.6T 2007-10-30 2008-10-30 Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis DK2217704T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007052114A DE102007052114B4 (de) 2007-10-30 2007-10-30 Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
PCT/DE2008/001759 WO2009056116A1 (de) 2007-10-30 2008-10-30 Verfahren zur förderung der angiogenese, vaskularisierung oder gefässreparatur oder zur hemmung der tumorangiogenese

Publications (1)

Publication Number Publication Date
DK2217704T3 true DK2217704T3 (en) 2017-03-13

Family

ID=40375407

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08844273.6T DK2217704T3 (en) 2007-10-30 2008-10-30 Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis
DK13179144.4T DK2684955T3 (en) 2007-10-30 2008-10-30 Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13179144.4T DK2684955T3 (en) 2007-10-30 2008-10-30 Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis

Country Status (16)

Country Link
US (4) US8258113B2 (enExample)
EP (3) EP2684956B1 (enExample)
JP (4) JP5898843B2 (enExample)
CA (1) CA2704290C (enExample)
CY (2) CY1120360T1 (enExample)
DE (1) DE102007052114B4 (enExample)
DK (2) DK2217704T3 (enExample)
ES (2) ES2618203T3 (enExample)
HR (2) HRP20170346T1 (enExample)
HU (2) HUE031559T2 (enExample)
LT (2) LT2217704T (enExample)
NO (1) NO2684955T3 (enExample)
PL (2) PL2684955T3 (enExample)
PT (2) PT2684955T (enExample)
SI (2) SI2217704T1 (enExample)
WO (1) WO2009056116A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DK2056845T3 (da) 2006-08-08 2017-11-27 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur og anvendelse af 5'-phosphat-oligonukleotider
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2012065024A1 (en) * 2010-11-11 2012-05-18 University Of Miami Compositions, cells, kits and methods for autologous stem cell therapy
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
WO2014028493A2 (en) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
PL2759595T3 (pl) * 2013-01-24 2017-09-29 Pierre Fabre Médicament S.A.S. Kompozycja zawierająca kapsułkowany antagomir
EP2970968B1 (en) 2013-03-15 2018-01-10 Miragen Therapeutics, Inc. Bridged bicyclic nucleosides
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
JP6878274B2 (ja) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
US20160122762A1 (en) * 2014-10-27 2016-05-05 University Of Iowa Research Foundation Methods of treating atherosclerosis
SG11201705907XA (en) * 2015-01-20 2017-08-30 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
CN107586784B (zh) * 2016-07-08 2020-08-25 田小利 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018195210A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
WO2019167995A1 (ja) * 2018-02-28 2019-09-06 国立大学法人東京医科歯科大学 虚血病変部位特異的な遺伝子治療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
EP2290070B1 (en) * 2004-05-28 2015-03-25 Asuragen, Inc. Methods and compositions involving microRNA
US20090209621A1 (en) * 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
ES2442890T3 (es) * 2006-07-13 2014-02-14 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008070082A2 (en) * 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2009004632A2 (en) * 2007-07-05 2009-01-08 Yeda Research And Development Co. Ltd. Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
AU2008275877B2 (en) * 2007-07-18 2015-01-22 The Regents Of The University Of Colorado, A Body Corporate Differential expression of microRNAs in nonfailing versus failing human hearts
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Also Published As

Publication number Publication date
US8258113B2 (en) 2012-09-04
US20160237433A1 (en) 2016-08-18
DE102007052114B4 (de) 2011-01-05
EP2217704B1 (de) 2016-12-07
LT2684955T (lt) 2017-12-27
US20100324118A1 (en) 2010-12-23
PL2684955T3 (pl) 2018-05-30
DK2684955T3 (en) 2017-12-18
US8912158B2 (en) 2014-12-16
ES2618203T3 (es) 2017-06-21
CY1120360T1 (el) 2019-07-10
US20120322856A1 (en) 2012-12-20
JP2016199565A (ja) 2016-12-01
US9279123B2 (en) 2016-03-08
EP2217704A1 (de) 2010-08-18
PT2684955T (pt) 2017-12-13
HRP20171874T1 (hr) 2018-01-12
EP2684955A1 (de) 2014-01-15
CA2704290A1 (en) 2009-05-07
NO2684955T3 (enExample) 2018-02-03
JP2014196317A (ja) 2014-10-16
US20150018407A1 (en) 2015-01-15
SI2217704T1 (sl) 2017-05-31
JP2018083817A (ja) 2018-05-31
PT2217704T (pt) 2017-03-15
SI2684955T1 (en) 2018-01-31
ES2651287T3 (es) 2018-01-25
WO2009056116A1 (de) 2009-05-07
EP2684955B1 (de) 2017-09-06
JP5898843B2 (ja) 2016-04-06
LT2217704T (lt) 2017-04-10
DE102007052114A1 (de) 2009-05-07
HUE031559T2 (hu) 2017-07-28
CA2704290C (en) 2018-05-15
EP2684956A1 (de) 2014-01-15
JP2011500858A (ja) 2011-01-06
HUE037494T2 (hu) 2018-08-28
CY1120226T1 (el) 2018-12-12
HRP20170346T1 (hr) 2017-04-21
PL2217704T3 (pl) 2017-06-30
EP2684956B1 (de) 2017-08-23
US9862949B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
DK2217704T3 (en) Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis
Da Costa Martins et al. MicroRNAs in control of cardiac hypertrophy
EP2454370B1 (en) Microrna-24
Clark et al. MicroRNAs in the myocyte enhancer factor 2 (MEF2)-regulated Gtl2-Dio3 noncoding RNA locus promote cardiomyocyte proliferation by targeting the transcriptional coactivator Cited2
EP2794882B1 (en) Micrornas for cardiac regeneration through induction of cardiac myocyte proliferation
CA3134991A1 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
EP2504434B1 (en) Pharmaceutical composition comprising mirna-100 and its use in the modulation of blood vessel growth and endothelial inflammation
US20120282326A1 (en) Compositions and methods related to mirna in diabetic conditions
JP2009545300A (ja) ｍｉＲＮＡの使用及びｍｉＲＮＡを含む組成物
CN102266569B (zh) miR-199a及其抑制剂的应用
Cicchillitti et al. Valeria Ambrosino3, Annalisa Antonini2, Maurizio C. Capogrossi2, Carlo Gaetano4, Giulia Piaggio3, and Fabio Martelli1
HK1193843B (en) Method for promoting angiogenesis, vascularisation or vessel repair or for inhibiting tumour angiogenesis
Videira Cardiac ischemia-reperfusion injury: in vitro models and regulation by microRNAs
HK1193844A (en) Methods for promoting angiogenesis, vascularisation or vessel repair or for inhibiting tumour angiogenesis
HK1193843A (en) Method for promoting angiogenesis, vascularisation or vessel repair or for inhibiting tumour angiogenesis